We read with interest the recent article by Jerrard-Dunne et al in which they established race-specific ranges for thrombophilia markers in blacks. 1 Testing for hereditary thrombophilia has been advocated for a myriad of both arterial and venous disorders and the association with venous thromboembolism (VTE) but not arterial disease has been established in well-conducted studies. 2 A common feature in thrombophilia research is the tendency to ignore the potential for ethnicity to influence disease. The conventional hereditary thrombophilia tests performed in the United Kingdom include a range of investigations: genotyping for factor V Leiden (FVL) and prothrombin mutations, and measurement of protein C (PC), protein S (PS), and antithrombin (AT) phenotype. These prothrombotic markers are informative in 30% to 70% of Europeans presenting with VTE and recurrent VTE 3 but are rare in black populations. 4,5 This is supported by data from our own institution in which only 13 of 142 black subjects (9.1%) with a history of VTE had a thrombophilic marker, compared with 30% of white subjects. 6 Of the positive thrombophilia tests in blacks (30% African and 70% Caribbean), 4 had PS deficiency, 6 had PC deficiency, 1 had AT deficiency, and 2 were heterozygous for FVL. In their study, Jerrard-Dunne et al have found that a significant proportion of healthy black controls would be misdiagnosed as having PC, PS, and possibly AT deficiency using reference ranges derived from white populations. This will be of concern to those of us involved in the treatment of VTE in multi-ethnic populations who are aware of both the psychosocial and medical consequences that may associated with the diagnosis of a "genetic disorder." Negative results in black patients undergoing thrombophilia testing may lead to a false reassurance of normality, and positive results using inappropriate reference ranges should now be viewed as unreliable.
